Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onset
Our results identified thresholds of change in βGS associated with a clinically significant impact on glycaemic management after intervention and suggest that baseline βGS in association with clinical and demographic parameters may be applied to identify individuals who are more likely to respond to an intervention.
Authors
- Andrea Mari
- Carmella Evans-Molina
- Stephen E. Gitelman
- Ele Ferrannini
Institutions
- University of California, San Francisco (US)
- Istituto di Fisiologia Clinica (IT)
- Richard L. Roudebush VA Medical Center (US)
- Neuroscience Institute (IT)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Diabetologia
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1007/s00125-026-06703-8
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- School of Medicine, Indiana University